IDH2 and neoplasm: Based on the difference in the IDH1/2 mutational states between the primary and secondary tumors, we could conclude that secondary tumor with IDH1/2 wild-type did not develop from the primary tumor with IDH2 mutation, but the secondary tumor was a de novo tumor that was related to the previous radiation therapy.